Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors.
Identifieur interne : 002E80 ( PubMed/Corpus ); précédent : 002E79; suivant : 002E81Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors.
Auteurs : Shuwen Liu ; Gengfu Xiao ; Yibang Chen ; Yuxian He ; Jinkui Niu ; Carlos R. Escalante ; Huabao Xiong ; James Farmar ; Asim K. Debnath ; Po Tien ; Shibo JiangSource :
- Lancet (London, England) [ 1474-547X ] ; 2004.
English descriptors
- KwdEn :
- Anti-HIV Agents (chemistry), Anti-HIV Agents (pharmacology), Cells, Cultured, Chemical Fractionation, Chromatography, High Pressure Liquid, Circular Dichroism, Electrophoresis, Polyacrylamide Gel, HIV Envelope Protein gp41 (chemistry), HIV Envelope Protein gp41 (drug effects), HIV Envelope Protein gp41 (metabolism), HIV Envelope Protein gp41 (pharmacology), Humans, Membrane Fusion (drug effects), Membrane Fusion (physiology), Membrane Glycoproteins (chemistry), Membrane Glycoproteins (metabolism), Membrane Glycoproteins (pharmacology), Oligopeptides (chemistry), Oligopeptides (drug effects), Oligopeptides (metabolism), Protein Conformation (drug effects), SARS Virus (chemistry), SARS Virus (drug effects), SARS Virus (metabolism), Sequence Homology, Nucleic Acid, Severe Acute Respiratory Syndrome (drug therapy), Severe Acute Respiratory Syndrome (metabolism), Severe Acute Respiratory Syndrome (prevention & control), Spike Glycoprotein, Coronavirus, Surface Plasmon Resonance, Viral Envelope Proteins (chemistry), Viral Envelope Proteins (metabolism), Viral Envelope Proteins (pharmacology), Viral Fusion Proteins (chemistry), Viral Fusion Proteins (metabolism).
- MESH :
- chemical , chemistry : Anti-HIV Agents, HIV Envelope Protein gp41, Membrane Glycoproteins, Oligopeptides, Viral Envelope Proteins, Viral Fusion Proteins.
- chemical , drug effects : HIV Envelope Protein gp41, Oligopeptides.
- chemical , metabolism : HIV Envelope Protein gp41, Membrane Glycoproteins, Oligopeptides, Viral Envelope Proteins, Viral Fusion Proteins.
- chemical , pharmacology : Anti-HIV Agents, HIV Envelope Protein gp41, Membrane Glycoproteins, Viral Envelope Proteins.
- chemistry : SARS Virus.
- drug effects : Membrane Fusion, Protein Conformation, SARS Virus.
- drug therapy : Severe Acute Respiratory Syndrome.
- metabolism : SARS Virus, Severe Acute Respiratory Syndrome.
- physiology : Membrane Fusion.
- prevention & control : Severe Acute Respiratory Syndrome.
- Cells, Cultured, Chemical Fractionation, Chromatography, High Pressure Liquid, Circular Dichroism, Electrophoresis, Polyacrylamide Gel, Humans, Sequence Homology, Nucleic Acid, Spike Glycoprotein, Coronavirus, Surface Plasmon Resonance.
Abstract
Studies on the fusion-inhibitory peptides derived from the heptad repeat 1 and 2 (HR1 and HR2) regions of the HIV-1 envelope glycoprotein gp41 provided crucial information on the viral fusogenic mechanism. We used a similar approach to study the fusogenic mechanism of severe-acute-respiratory-syndrome-associated coronavirus (SARS-CoV).
DOI: 10.1016/S0140-6736(04)15788-7
PubMed: 15043961
Links to Exploration step
pubmed:15043961Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors.</title><author><name sortKey="Liu, Shuwen" sort="Liu, Shuwen" uniqKey="Liu S" first="Shuwen" last="Liu">Shuwen Liu</name><affiliation><nlm:affiliation>Lindsley F Kimball Research Institute, New York Blood Center, New York, NY 10021, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Xiao, Gengfu" sort="Xiao, Gengfu" uniqKey="Xiao G" first="Gengfu" last="Xiao">Gengfu Xiao</name></author><author><name sortKey="Chen, Yibang" sort="Chen, Yibang" uniqKey="Chen Y" first="Yibang" last="Chen">Yibang Chen</name></author><author><name sortKey="He, Yuxian" sort="He, Yuxian" uniqKey="He Y" first="Yuxian" last="He">Yuxian He</name></author><author><name sortKey="Niu, Jinkui" sort="Niu, Jinkui" uniqKey="Niu J" first="Jinkui" last="Niu">Jinkui Niu</name></author><author><name sortKey="Escalante, Carlos R" sort="Escalante, Carlos R" uniqKey="Escalante C" first="Carlos R" last="Escalante">Carlos R. Escalante</name></author><author><name sortKey="Xiong, Huabao" sort="Xiong, Huabao" uniqKey="Xiong H" first="Huabao" last="Xiong">Huabao Xiong</name></author><author><name sortKey="Farmar, James" sort="Farmar, James" uniqKey="Farmar J" first="James" last="Farmar">James Farmar</name></author><author><name sortKey="Debnath, Asim K" sort="Debnath, Asim K" uniqKey="Debnath A" first="Asim K" last="Debnath">Asim K. Debnath</name></author><author><name sortKey="Tien, Po" sort="Tien, Po" uniqKey="Tien P" first="Po" last="Tien">Po Tien</name></author><author><name sortKey="Jiang, Shibo" sort="Jiang, Shibo" uniqKey="Jiang S" first="Shibo" last="Jiang">Shibo Jiang</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2004">2004</date><idno type="RBID">pubmed:15043961</idno><idno type="pmid">15043961</idno><idno type="doi">10.1016/S0140-6736(04)15788-7</idno><idno type="wicri:Area/PubMed/Corpus">002E80</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002E80</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors.</title><author><name sortKey="Liu, Shuwen" sort="Liu, Shuwen" uniqKey="Liu S" first="Shuwen" last="Liu">Shuwen Liu</name><affiliation><nlm:affiliation>Lindsley F Kimball Research Institute, New York Blood Center, New York, NY 10021, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Xiao, Gengfu" sort="Xiao, Gengfu" uniqKey="Xiao G" first="Gengfu" last="Xiao">Gengfu Xiao</name></author><author><name sortKey="Chen, Yibang" sort="Chen, Yibang" uniqKey="Chen Y" first="Yibang" last="Chen">Yibang Chen</name></author><author><name sortKey="He, Yuxian" sort="He, Yuxian" uniqKey="He Y" first="Yuxian" last="He">Yuxian He</name></author><author><name sortKey="Niu, Jinkui" sort="Niu, Jinkui" uniqKey="Niu J" first="Jinkui" last="Niu">Jinkui Niu</name></author><author><name sortKey="Escalante, Carlos R" sort="Escalante, Carlos R" uniqKey="Escalante C" first="Carlos R" last="Escalante">Carlos R. Escalante</name></author><author><name sortKey="Xiong, Huabao" sort="Xiong, Huabao" uniqKey="Xiong H" first="Huabao" last="Xiong">Huabao Xiong</name></author><author><name sortKey="Farmar, James" sort="Farmar, James" uniqKey="Farmar J" first="James" last="Farmar">James Farmar</name></author><author><name sortKey="Debnath, Asim K" sort="Debnath, Asim K" uniqKey="Debnath A" first="Asim K" last="Debnath">Asim K. Debnath</name></author><author><name sortKey="Tien, Po" sort="Tien, Po" uniqKey="Tien P" first="Po" last="Tien">Po Tien</name></author><author><name sortKey="Jiang, Shibo" sort="Jiang, Shibo" uniqKey="Jiang S" first="Shibo" last="Jiang">Shibo Jiang</name></author></analytic><series><title level="j">Lancet (London, England)</title><idno type="eISSN">1474-547X</idno><imprint><date when="2004" type="published">2004</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anti-HIV Agents (chemistry)</term><term>Anti-HIV Agents (pharmacology)</term><term>Cells, Cultured</term><term>Chemical Fractionation</term><term>Chromatography, High Pressure Liquid</term><term>Circular Dichroism</term><term>Electrophoresis, Polyacrylamide Gel</term><term>HIV Envelope Protein gp41 (chemistry)</term><term>HIV Envelope Protein gp41 (drug effects)</term><term>HIV Envelope Protein gp41 (metabolism)</term><term>HIV Envelope Protein gp41 (pharmacology)</term><term>Humans</term><term>Membrane Fusion (drug effects)</term><term>Membrane Fusion (physiology)</term><term>Membrane Glycoproteins (chemistry)</term><term>Membrane Glycoproteins (metabolism)</term><term>Membrane Glycoproteins (pharmacology)</term><term>Oligopeptides (chemistry)</term><term>Oligopeptides (drug effects)</term><term>Oligopeptides (metabolism)</term><term>Protein Conformation (drug effects)</term><term>SARS Virus (chemistry)</term><term>SARS Virus (drug effects)</term><term>SARS Virus (metabolism)</term><term>Sequence Homology, Nucleic Acid</term><term>Severe Acute Respiratory Syndrome (drug therapy)</term><term>Severe Acute Respiratory Syndrome (metabolism)</term><term>Severe Acute Respiratory Syndrome (prevention & control)</term><term>Spike Glycoprotein, Coronavirus</term><term>Surface Plasmon Resonance</term><term>Viral Envelope Proteins (chemistry)</term><term>Viral Envelope Proteins (metabolism)</term><term>Viral Envelope Proteins (pharmacology)</term><term>Viral Fusion Proteins (chemistry)</term><term>Viral Fusion Proteins (metabolism)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Anti-HIV Agents</term><term>HIV Envelope Protein gp41</term><term>Membrane Glycoproteins</term><term>Oligopeptides</term><term>Viral Envelope Proteins</term><term>Viral Fusion Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>HIV Envelope Protein gp41</term><term>Oligopeptides</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>HIV Envelope Protein gp41</term><term>Membrane Glycoproteins</term><term>Oligopeptides</term><term>Viral Envelope Proteins</term><term>Viral Fusion Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Anti-HIV Agents</term><term>HIV Envelope Protein gp41</term><term>Membrane Glycoproteins</term><term>Viral Envelope Proteins</term></keywords><keywords scheme="MESH" qualifier="chemistry" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Membrane Fusion</term><term>Protein Conformation</term><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Membrane Fusion</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Cells, Cultured</term><term>Chemical Fractionation</term><term>Chromatography, High Pressure Liquid</term><term>Circular Dichroism</term><term>Electrophoresis, Polyacrylamide Gel</term><term>Humans</term><term>Sequence Homology, Nucleic Acid</term><term>Spike Glycoprotein, Coronavirus</term><term>Surface Plasmon Resonance</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Studies on the fusion-inhibitory peptides derived from the heptad repeat 1 and 2 (HR1 and HR2) regions of the HIV-1 envelope glycoprotein gp41 provided crucial information on the viral fusogenic mechanism. We used a similar approach to study the fusogenic mechanism of severe-acute-respiratory-syndrome-associated coronavirus (SARS-CoV).</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15043961</PMID><DateCompleted><Year>2004</Year><Month>04</Month><Day>27</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1474-547X</ISSN><JournalIssue CitedMedium="Internet"><Volume>363</Volume><Issue>9413</Issue><PubDate><Year>2004</Year><Month>Mar</Month><Day>20</Day></PubDate></JournalIssue><Title>Lancet (London, England)</Title><ISOAbbreviation>Lancet</ISOAbbreviation></Journal><ArticleTitle>Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors.</ArticleTitle><Pagination><MedlinePgn>938-47</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Studies on the fusion-inhibitory peptides derived from the heptad repeat 1 and 2 (HR1 and HR2) regions of the HIV-1 envelope glycoprotein gp41 provided crucial information on the viral fusogenic mechanism. We used a similar approach to study the fusogenic mechanism of severe-acute-respiratory-syndrome-associated coronavirus (SARS-CoV).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We tested the inhibitory activity against infection of two sets of peptides corresponding to sequences of SARS-CoV spike protein HR1 and HR2 regions and investigated the interactions between the HR1 and HR2 peptides by surface plasmon resonance, sedimentation equilibration analysis, circular dichroism, native polyacrylamide-gel electrophoresis, size exclusion high-performance liquid chromatography, and computer-aided homology modelling and molecule docking analysis.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">One peptide, CP-1, derived from the HR2 region, inhibited SARS-CoV infection in the micromolar range. CP-1 bound with high affinity to a peptide from the HR1 region, NP-1. CP-1 alone had low alpha-helicity and self-associated to form a trimer in phosphate buffer (pH 7.2). CP-1 and NP-1 mixed in equimolar concentrations formed a six-helix bundle, similar to the fusogenic core structure of HIV-1 gp41.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">After binding to the target cell, the transmembrane spike protein might change conformation by association between the HR1 and HR2 regions to form an oligomeric structure, leading to fusion between the viral and target-cell membranes. At the prefusion intermediate state, CP-1 could bind to the HR1 region and interfere with the conformational changes, resulting in inhibition of SARS-CoV fusion with the target cells. CP-1 might be modifiable to increase its anti-SARS-CoV activity and could be further developed as an antiviral agent for treatment or prophylaxis of SARS-CoV infection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Shuwen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Lindsley F Kimball Research Institute, New York Blood Center, New York, NY 10021, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiao</LastName><ForeName>Gengfu</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yibang</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Yuxian</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Niu</LastName><ForeName>Jinkui</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Escalante</LastName><ForeName>Carlos R</ForeName><Initials>CR</Initials></Author><Author ValidYN="Y"><LastName>Xiong</LastName><ForeName>Huabao</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Farmar</LastName><ForeName>James</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Debnath</LastName><ForeName>Asim K</ForeName><Initials>AK</Initials></Author><Author ValidYN="Y"><LastName>Tien</LastName><ForeName>Po</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Shibo</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet</MedlineTA><NlmUniqueID>2985213R</NlmUniqueID><ISSNLinking>0140-6736</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019380">Anti-HIV Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C106243">CP-1 peptide</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015700">HIV Envelope Protein gp41</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009842">Oligopeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014760">Viral Fusion Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D019380" MajorTopicYN="N">Anti-HIV Agents</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005591" MajorTopicYN="N">Chemical Fractionation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002851" MajorTopicYN="N">Chromatography, High Pressure Liquid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002942" MajorTopicYN="N">Circular Dichroism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004591" MajorTopicYN="N">Electrophoresis, Polyacrylamide Gel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015700" MajorTopicYN="N">HIV Envelope Protein gp41</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008561" MajorTopicYN="N">Membrane Fusion</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009842" MajorTopicYN="N">Oligopeptides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011487" MajorTopicYN="N">Protein Conformation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012689" MajorTopicYN="N">Sequence Homology, Nucleic Acid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020349" MajorTopicYN="N">Surface Plasmon Resonance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014760" MajorTopicYN="N">Viral Fusion Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>3</Month><Day>27</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>4</Month><Day>28</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>3</Month><Day>27</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15043961</ArticleId><ArticleId IdType="doi">10.1016/S0140-6736(04)15788-7</ArticleId><ArticleId IdType="pii">S0140-6736(04)15788-7</ArticleId><ArticleId IdType="pmc">PMC7140173</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Biochem J. 1998 Mar 1;330 ( Pt 2):983-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9480919</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2003 Oct 10;302(5643):276-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12958366</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 2003 Nov 27;426(6965):450-4</Citation><ArticleIdList><ArticleId IdType="pubmed">14647384</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 1993 Sep 15;195(2):533-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8373393</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Gen Virol. 2002 Mar;83(Pt 3):623-629</Citation><ArticleIdList><ArticleId IdType="pubmed">11842257</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Curr Pharm Des. 2002;8(8):563-80</Citation><ArticleIdList><ArticleId IdType="pubmed">11945159</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1953-66</Citation><ArticleIdList><ArticleId IdType="pubmed">12690092</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 1997 Apr;71(4):3129-37</Citation><ArticleIdList><ArticleId IdType="pubmed">9060676</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Adv Virus Res. 1997;48:1-100</Citation><ArticleIdList><ArticleId IdType="pubmed">9233431</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1948-51</Citation><ArticleIdList><ArticleId IdType="pubmed">12748314</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2003 Mar 14;302(3):469-75</Citation><ArticleIdList><ArticleId IdType="pubmed">12615056</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biochemistry. 2003 May 6;42(17):4945-53</Citation><ArticleIdList><ArticleId IdType="pubmed">12718536</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 1992 Mar 15;89(6):2195-9</Citation><ArticleIdList><ArticleId IdType="pubmed">1549581</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biophys J. 1981 Dec;36(3):575-88</Citation><ArticleIdList><ArticleId IdType="pubmed">7326325</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15613-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9861018</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Mol Biol. 1993 Dec 5;234(3):779-815</Citation><ArticleIdList><ArticleId IdType="pubmed">8254673</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Protein Sci. 1997 Jun;6(6):1179-89</Citation><ArticleIdList><ArticleId IdType="pubmed">9194178</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>AIDS Res Hum Retroviruses. 1989 Aug;5(4):431-40</Citation><ArticleIdList><ArticleId IdType="pubmed">2788443</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Med Chem. 1999 Aug 26;42(17):3203-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10464007</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 1992 Nov 6;258(5084):917-24</Citation><ArticleIdList><ArticleId IdType="pubmed">1439803</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16249-54</Citation><ArticleIdList><ArticleId IdType="pubmed">12444251</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Peptides. 2003 Sep;24(9):1303-13</Citation><ArticleIdList><ArticleId IdType="pubmed">14706544</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Pept Res. 1995 Nov-Dec;8(6):345-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8838418</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1967-76</Citation><ArticleIdList><ArticleId IdType="pubmed">12690091</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Cell. 1997 Apr 18;89(2):263-73</Citation><ArticleIdList><ArticleId IdType="pubmed">9108481</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biochemistry. 1995 Nov 21;34(46):14955-62</Citation><ArticleIdList><ArticleId IdType="pubmed">7578108</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nat Struct Biol. 1995 Dec;2(12):1075-82</Citation><ArticleIdList><ArticleId IdType="pubmed">8846219</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2001 Mar;75(6):2792-802</Citation><ArticleIdList><ArticleId IdType="pubmed">11222703</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10537-41</Citation><ArticleIdList><ArticleId IdType="pubmed">1438243</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):9770-4</Citation><ArticleIdList><ArticleId IdType="pubmed">7937889</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 1996 Sep 1;223(1):103-12</Citation><ArticleIdList><ArticleId IdType="pubmed">8806544</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>AIDS Res Hum Retroviruses. 2002 Sep 20;18(14):989-97</Citation><ArticleIdList><ArticleId IdType="pubmed">12396451</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2000 Nov;74(21):10194-201</Citation><ArticleIdList><ArticleId IdType="pubmed">11024148</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 1999 Oct;73(10):8152-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10482565</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Chin Sci Bull. 2003;48(10):941-948</Citation><ArticleIdList><ArticleId IdType="pubmed">32214698</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 1997 May 22;387(6631):426-30</Citation><ArticleIdList><ArticleId IdType="pubmed">9163431</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 1993 Sep 9;365(6442):113</Citation><ArticleIdList><ArticleId IdType="pubmed">8371754</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Cell. 1998 May 29;93(5):681-4</Citation><ArticleIdList><ArticleId IdType="pubmed">9630213</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Mol Biol. 1993 Jun 20;231(4):1049-67</Citation><ArticleIdList><ArticleId IdType="pubmed">8515464</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 1996 Jun 15;220(2):274-84</Citation><ArticleIdList><ArticleId IdType="pubmed">8661378</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2003 May 30;300(5624):1394-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12730500</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Methods Enzymol. 1996;266:525-39</Citation><ArticleIdList><ArticleId IdType="pubmed">8743704</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol Methods. 1999 Jun;80(1):85-96</Citation><ArticleIdList><ArticleId IdType="pubmed">10403680</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2003 Aug;77(16):8801-11</Citation><ArticleIdList><ArticleId IdType="pubmed">12885899</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2003 Apr 19;361(9366):1319-25</Citation><ArticleIdList><ArticleId IdType="pubmed">12711465</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8477-82</Citation><ArticleIdList><ArticleId IdType="pubmed">10411900</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2003 May 30;300(5624):1399-404</Citation><ArticleIdList><ArticleId IdType="pubmed">12730501</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nucleic Acids Res. 1997 Dec 15;25(24):4876-82</Citation><ArticleIdList><ArticleId IdType="pubmed">9396791</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002E80 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002E80 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:15043961
|texte= Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:15043961" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |